Comparative study of venlafaxine sustained-release capsules and citalopram tablet in the treatment of post-stroke depression
-
摘要: 目的 比较文拉法辛缓释胶囊与西肽普兰片治疗脑卒中后抑郁的疗效及安全性。 方法 将60例脑卒中后抑郁患者随机分为文拉法辛缓释胶囊(n=30)和西酞普兰片组(n=30),治疗8周,采用汉密顿抑郁量表(Hamilton rating scale for depression,HAMD)和不良反应量表(treatment emergent system scale,TESS)评定疗效及不良反应。 结果 治疗4~8周后两组患者HAMD评分均较治疗前显著降低(P<0.05),但两组间差异无统计学意义(P>0.05),文拉法辛组在2周末时HAMD评分较西肽普兰组有显著差异(P<0.05)。不良反应发生率及严重程度两组差异均无统计学意义(P>0.05)。 结论 两组总体疗效和不良反应均相近,文拉法辛起效较西酞普兰快。Abstract: Objective To compare the therapeutic effectiveness and safeness of venlafaxine sustained-release capsules and citalopram tablets in the treatment of post-stroke depression. Methods 60 patients were randomly divided into venlafaxine group (n=30)and citalomram group(n=30) for 8 weeks treatment. Hamilton rating scale for depression(HAMD) and treatment emergent system scale (TESS) were used to evaluate the efficacy and side effects, respectively. Results After 4-8 weeks of treatment,both scores of HAMD of the two groups decreased significantly(P<0.05),but there was no difference between the two groups(P>0.05). The total scores of HAMD in venlafaxine group were notably lower than citalopram group after 2 weeks(P<0.05). There was no significant difference in side effects between the two groups(P>0.05). Conclusion There was no significant difference in gross curative effect and side effects between two groups; venlafaxine worked faster compared to citalopram.
-
Key words:
- post-stroke depression /
- venlafaxine /
- citalopram
-
[1] 芮 雪,范晓华,潘卫萍.脑卒中后抑郁发生率及其相关因素的调查分析[J].医学信息,2012,23(6):1939-1940. [2] Johnson JL Minaik PA Nystrom KV,et al.Poststroke depression incidence and risk factors: an intergrave literature review[J].J Neurosci Nurs,2006,38(4 Suppl):316-327. [3] Jia H,Damush TM,Qin H,et al.The impact of poststroke depression on healthcare use by veterans with acute stroke[J].Stroke,2006,37:2796-2801. [4] Begre S,Traber M,Gerber M,et al.Change in pain severity with open label yenlafaxine use in patients with a depressive symptomatology: an observational study in primary care[J].Eur Psychiatr,2008,23(3):178-186. [5] 金卫东,冯 斌.文拉法辛治疗抑郁症的循证医学证据[J].四川精神卫生,2005,18(1):64. [6] 中华神经科学会,中华神经外科学会.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379. [7] 世界卫生组织. ICD-10精神与行为障碍分类[M].北京:人民卫生出版社,1993:54. [8] 周国平,李 丹.脑卒中后抑郁的相关因素调查[J].中国误诊学杂志,2009,9(31):7807. [9] 沈渔邨. 精神病学[M].5版.北京:人民卫生出版社,2009:857. [10] 彭代辉,黄 佳.文拉法辛缓释片与文拉法辛缓释胶囊治疗抑郁症的随机、双盲对照研究[J].中国新药与临床杂志,2013,32(4):322. -
点击查看大图
计量
- 文章访问数: 2952
- HTML全文浏览量: 455
- PDF下载量: 351
- 被引次数: 0
下载:
